Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
127.60    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.20 (0.945%)
Market Cap: £531.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

31 Jul 2024 07:00

RNS Number : 4227Y
James Halstead PLC
31 July 2024
 

 

31 July 2024

 

 

JAMES HALSTEAD PLC (the "Company")

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2024.

 

The Company is fully confident of exceeding the prior year comparatives for profit, cash levels and dividend, with improved profitability seen in the first half continuing into H2.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring that is sold into the healthcare, education and other institutional sectors. Regionally sales into the Middle East and the Americas have been particularly buoyant. Some of the Company's products are focused on domestic sectors and performance of these products have been weaker in several territories - the UK and Europe being the most significant.

 

Notwithstanding this drag on performance the Group's productive output, gains on product mix and cost control of overheads have bolstered margins.

 

There have been gains on lower raw material pricing although energy costs, principally electricity, remain high. Notwithstanding the fall in raw materials costs during the year these input costs, in general, are around 50% ahead of June 2020 levels.

 

Operationally, the widely reported disruption to shipping in the Red Sea has lengthened delivery times and increased costs across the sector, which is particularly difficult for our APAC markets. As a result stock in transit has increased and in response we are holding stocks in the our overseas marketplaces at higher than normal levels.

 

 

In summary, profit before tax will be at record levels and in line with (upwardly revised) market expectations.

 

The Company expects to announce its results for the year ended 30 June 2024 on 1 October 2024.

 

 

The Company also announces that its Nominated Adviser and Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKKBKDBKDDON
Date   Source Headline
16th Mar 20153:46 pmRNSNotice of Interim Results
3rd Mar 20153:00 pmRNSTotal Voting Rights
30th Jan 20157:00 amRNSPre Close Trading Statement
6th Jan 20154:11 pmRNSBlocklisting Interim Review
6th Jan 201511:21 amRNSTotal Voting Rights
5th Dec 20147:00 amRNSAGM Statement
3rd Nov 20147:00 amRNSTotal Voting Rights
24th Oct 20143:24 pmRNSAnnual Financial Report
1st Oct 20149:25 amRNSTotal Voting Rights
1st Oct 20147:00 amRNSPreliminary Results
27th Aug 20147:00 amRNSNotice of Preliminary Results
31st Jul 20147:00 amRNSPre-Close Trading Statement
21st Jul 20143:50 pmRNSDirectors' Shareholdings
17th Jul 20144:51 pmRNSDirectors exercise of share options
1st Jul 20147:00 amRNSBlocklisting Interim Review
1st Jul 20147:00 amRNSTotal Voting Rights
3rd Jun 20147:00 amRNSTotal Voting Rights
1st May 201411:10 amRNSTotal Voting Rights
31st Mar 20147:00 amRNSInterim Results
3rd Feb 20147:00 amRNSPre Close Trading Statement
20th Jan 20149:40 amRNSPurchase of own shares and directors' dealings
6th Jan 20144:30 pmRNSBlocklisting Interim Review
6th Dec 20137:00 amRNSAGM Statement
4th Nov 201311:00 amRNSTotal Voting Rights
28th Oct 20135:25 pmRNSAnnual Financial Report
28th Oct 20134:18 pmRNSDirectors exercise of share options
4th Oct 201312:40 pmRNSTotal Voting Rights
1st Oct 20137:00 amRNSPreliminary Announcement of Audited Results
23rd Sep 201312:55 pmRNSNotice of Preliminary Results
31st Jul 20137:00 amRNSPre-close Trading Statement
16th Jul 201312:00 pmRNSBlocklisting Interim Review
21st Jun 20134:35 pmRNSPrice Monitoring Extension
2nd May 201311:10 amRNSTotal Voting Rights
28th Mar 20137:00 amRNSInterim Results
1st Feb 201311:15 amRNSNotice of Interim Results Date Change
31st Jan 20134:00 pmRNSTotal Voting Rights
31st Jan 20137:00 amRNSPre-close Trading Statement
10th Jan 201311:00 amRNSIssue of Equity and Total Voting Rights
7th Jan 20139:00 amRNSBlocklisting Interim Review
11th Dec 20127:00 amRNSBonus Issue
7th Dec 20124:40 pmRNSSecond Price Monitoring Extn
7th Dec 20124:35 pmRNSPrice Monitoring Extension
7th Dec 20127:00 amRNSAGM Statement
3rd Dec 20127:00 amRNSTotal Voting Rights
1st Nov 20127:00 amRNSTotal Voting Rights
23rd Oct 20127:00 amRNSAnnual Financial Report
1st Oct 20127:00 amRNSPreliminary Audited Results
3rd Sep 20127:00 amRNSTotal Voting Rights
30th Jul 20127:00 amRNSPre-close Trading Statement
2nd Jul 20129:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.